News | Radiation Oncology | July 28, 2021

IntraOp Announces First Patients Enrolled in FLASH Clinical Trial

Impulse Trial is the first to evaluate the curative potential of the FLASH Effect

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

July 28, 2021 — IntraOp Medical Corporation announced that Lausanne University Hospital (CHUV, Switzerland) enrolled the first patients in the Impulse Trial: A phase I dose-escalation study of high dose rate radiotherapy with electrons in patients with skin metastases from melanoma. The trial is a key milestone for the groundbreaking research collaboration agreement between IntraOp and the CHUV, executed in 2020. The Impulse Trial is the first in the world to evaluate the potential of leveraging the biological phenomenon known as the "FLASH Effect" to provide radiotherapy with curative intent to radio-resistant cancers.

To conduct the study, researchers will utilize the IntraOp Mobetron platform modified to deliver precision electron beam therapy at high dose rates to produce the FLASH effect. "Leveraging their vast experience studying FLASH with an experimental LINAC, the CHUV's researchers have diligently worked through the past year to prepare the FLASH capability of the Mobetron for biological and now human clinical work," stated Kenneth Brooks, Ph.D. Vice President of Sales and Corporate Strategy at IntraOp. "With its fine beam structure control capabilities now validated, the Mobetron is the clear choice for researchers who, as those of the CHUV, are looking to explore possible effects of changing fine structure on the basic science that underlies this biologic effect and thus expands their institution's research capabilities into FLASH with a clear path to clinical translation."

Scientists and clinician-researchers from CHUV are world-renowned pioneers in the characterization of the FLASH effect, having published numerous groundbreaking studies in animal testing as well as the first human treatment. In preclinical studies, the FLASH effect has demonstrated several biological benefits and an improved therapeutic index by producing a protective effect for normal tissue at certain ultra-high dose rates and volumes. Professor Jean Bourhis, head of radiation oncology and principal investigator noted: "The Impulse Trial is the first in a series of clinical trials we have outlined to better understand the potential of the FLASH effect. Melanoma is one of the most radio-resistant cancers and curative therapy with conventional radiotherapy is rarely possible. By leveraging the FLASH effect, we may be able to optimize the therapeutic ratio and escalate the irradiation dose to completely kill cancer cells with a protective effect on normal tissue."

 "The Impulse trial is a major step forward for FLASH research and we congratulate Prof. Bourhis, Dr. Vozenin, Dr. Moeckli, and the rest of the team at CHUV in their ongoing achievements to realize this breakthrough," said Derek T. DeScioli, Chief Executive Officer of IntraOp. "With our advanced electron therapy technology, commitment to patient-driven innovation, and growing cohort of research collaborators we are excited to be leading this new frontier in radiation oncology," added Mr. DeScioli.

Note: IntraOp's High Dose Rate (HDR) functionality is for investigational use only and is not approved for routine clinical use.

For more information: www.intraop.com

Related Content

Sun Nuclear's Absolute Dosimetric QA uses calibrated EPID data to enable true dosimetric in-vivo monitoring, creating a fully independent absolute dosimetric QA of patient treatments.

Sun Nuclear's Absolute Dosimetric QA uses calibrated EPID data to enable true dosimetric in-vivo monitoring, creating a fully independent absolute dosimetric QA of patient treatments.

Feature | Radiation Therapy | September 14, 2021 | By Dave Fornell, Editor
To maintain safety in radiation therap...
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Laws designed to help women with increased risk for missed breast cancer diagnoses may help catch the disease earlier, according to Penn State College of Medicine researchers.

Getty Images | AleksandarNakic

News | Breast Imaging | September 09, 2021
September 9, 2021 — Laws designed to help women with increased risk for...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
62-Year-Old Woman Who Underwent Hysterectomy for Uterine Cancer: Sagittal chest CT images demonstrate measurement of right (A) and left (B) lung length at hilar level from apex to diaphragmatic dome. Right lung length was 20.1 cm for reader 1 and 20.0 cm for reader 2; left lung length was 21.7 cm for reader 1 and 21.3 cm for reader 2. Patient did not require postoperative mechanical ventilation.

62-Year-Old Woman Who Underwent Hysterectomy for Uterine Cancer: Sagittal chest CT images demonstrate measurement of right (A) and left (B) lung length at hilar level from apex to diaphragmatic dome. Right lung length was 20.1 cm for reader 1 and 20.0 cm for reader 2; left lung length was 21.7 cm for reader 1 and 21.3 cm for reader 2. Patient did not require postoperative mechanical ventilation.

News | Computed Tomography (CT) | September 07, 2021